Levomer (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade stops bacterial cell division, leading to rapid bactericidal activity against a wide range of Gram‑positive and Gram‑negative ocular pathogens.

The dosing regimen for Levomer is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The product is supplied as eye drops and should be administered exactly as directed on the prescription label.

Safety data for ocular levofloxacin in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant or nursing should discuss use with their healthcare provider.

To order Levomer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as ciprofloxacin or ofloxacin, levofloxacin offers broader Gram‑negative coverage and a lower propensity for resistance development. It also provides convenient once‑ or twice‑daily dosing schedules, which can improve patient adherence.

Levomer should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and discard any solution that appears discolored or contains particles.

Levomer is applied as eye drops. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) according to the dosing schedule indicated by the prescriber, typically avoiding contact with the eyelid or lashes to maintain sterility.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration or perforation, tendon rupture, and systemic hypersensitivity reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience intense eye pain, swelling, or systemic symptoms.

Levomer should not be used by individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is also advised for patients with pre‑existing corneal epithelial defects or those receiving concurrent topical corticosteroids.